Press Releases Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
2.91 ^USD	+0.69%		-0.51%	+55.19%

02/05	Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	Protara Therapeutics, Inc. announced that it has received $44.998327 million in funding from a group of investors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protara Therapeutics: Q1 Earnings Snapshot	02/05	AQ
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update	02/05	AQ
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing	05/04	AQ
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	05/04	AQ
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	05/04	AQ
Protara Therapeutics: Q4 Earnings Snapshot	13/03	AQ
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	13/03	AQ
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	28/02	AQ
Protara Therapeutics to Participate in Upcoming Investor Conferences	31/01	AQ
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology	30/11	AQ
Protara Therapeutics: Q3 Earnings Snapshot	03/11	AQ
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update	03/11	AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations	23/23/23	AQ
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/23/09	AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ	20/23/20	AQ
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	05/23/05	AQ
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update	03/23/03	AQ
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ	15/23/15	AQ
Protara Therapeutics: Q1 Earnings Snapshot	04/23/04	AQ
PROTARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	04/23/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Press Releases

Filters